DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 204.3

Change

+3.05 (+1.52)%

Market Cap

USD 0.14B

Volume

2.66K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.62 (+1.38%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.38 (+0.38%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.25 (+1.06%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.15 (+1.17%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.06 (+1.13%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.21 (+0.91%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.04 (+0.28%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.66 (+1.20%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.02 (+0.24%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.27 (+0.22%)

USD 12.26B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.04% 26% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.04% 31% F 30% F
Trailing 12 Months  
Capital Gain -12.62% 8% B- 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.62% 11% F 16% F
Trailing 5 Years  
Capital Gain 24.68% 36% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.68% 37% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 9.57% 64% D 64% D
Dividend Return 9.57% 63% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.81% 66% D+ 74% C
Risk Adjusted Return 108.68% 93% A 94% A
Market Capitalization 0.14B 45% F 34% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.